Cargando…

Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis

BACKGROUND: Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their comparative efficacy and safety during induction and maintenance through network meta-analysis. METHODS: Using Bayesian methods, endpoints of clinical remission a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panaccione, Remo, Collins, Eric B, Melmed, Gil Y, Vermeire, Severine, Danese, Silvio, Higgins, Peter D R, Kwon, Christina S, Zhou, Wen, Ilo, Dapo, Sharma, Dolly, Sanchez Gonzalez, Yuri, Wang, Si-Tien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045885/ https://www.ncbi.nlm.nih.gov/pubmed/36998249 http://dx.doi.org/10.1093/crocol/otad009

Ejemplares similares

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
por: Panés, Julian, et al.
Publicado: (2023)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
por: Parkes, Gareth, et al.
Publicado: (2023)

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn’s Disease or Ulcerative Colitis in the United States
por: Ding, Zhijie, et al.
Publicado: (2022)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis
por: Kerur, Basavaraj, et al.
Publicado: (2017)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
por: Klepp, Pasquale, et al.
Publicado: (2018)

Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial
por: Schreiber, Stefan, et al.
Publicado: (2023)

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis
por: Zhao, Hong-Ying, et al.
Publicado: (2017)

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
por: Sands, Bruce E, et al.
Publicado: (2023)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

Clinical course of ulcerative colitis patients who develop acute pancreatitis
por: Kim, Jong Wook, et al.
Publicado: (2017)

Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
por: van Langenberg, Daniel R, et al.
Publicado: (2020)

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis
por: He, Xu-Xia, et al.
Publicado: (2021)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan
por: Itabashi, Michio, et al.
Publicado: (2021)

Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
por: Sharma, Shreyak, et al.
Publicado: (2023)

Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression
por: Jovanovic, Marina, et al.
Publicado: (2019)

Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis
por: Choi, Yong-Sung, et al.
Publicado: (2021)

Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis
por: Lopes, Mirella Brasil, et al.
Publicado: (2022)

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
por: Perin, Ramir Luan, et al.
Publicado: (2022)

Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists
por: Pudipeddi, Aviv, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dog6nig5t482n4u84htft6jq84